Member Bibliography/Bibliografía de Miembros
This page collects all the personal publications that CienciaPR members have uploaded to their profiles. You can also see all of the authors collected in these publications or all the keywords contained in these publications.
“Identification of a 251 gene expression signature that can accurately detect M. tuberculosis in patients with and without HIV co-infection.”, PLoS One, vol. 9, no. 2, p. e89925, 2014.
“Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.”, J Infect Dis, vol. 208, no. 2, p. 363, 2013.
“Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.”, J Infect Dis, vol. 207, no. 2, pp. 213-22, 2013.
“Antiretroviral therapy interruptions result in loss of protective humoral immunity to neoantigens in HIV-infected individuals.”, AIDS, vol. 26, no. 11, pp. 1355-62, 2012.
“Concurrent measures of total and integrated HIV DNA monitor reservoirs and ongoing replication in eradication trials.”, AIDS, vol. 26, no. 18, pp. 2295-306, 2012.
“Prioritizing CD4 count monitoring in response to ART in resource-constrained settings: a retrospective application of prediction-based classification.”, PLoS Med, vol. 9, no. 4, p. e1001207, 2012.
“Increased microbial translocation in ≤ 180 days old perinatally human immunodeficiency virus-positive infants as compared with human immunodeficiency virus-exposed uninfected infants of similar age.”, Pediatr Infect Dis J, vol. 30, no. 10, pp. 877-82, 2011.
“Metabolic and anthropometric parameters contribute to ART-mediated CD4+ T cell recovery in HIV-1-infected individuals: an observational study.”, J Int AIDS Soc, vol. 14, p. 37, 2011.
“Natural killer cell activation distinguishes Mycobacterium tuberculosis-mediated immune reconstitution syndrome from chronic HIV and HIV/MTB coinfection.”, J Acquir Immune Defic Syndr, vol. 58, no. 3, pp. 309-18, 2011.
“Randomized trial of time-limited interruptions of protease inhibitor-based antiretroviral therapy (ART) vs. continuous therapy for HIV-1 infection.”, PLoS One, vol. 6, no. 6, p. e21450, 2011.
“Association between HIV replication and serum leptin levels: an observational study of a cohort of HIV-1-infected South African women.”, J Int AIDS Soc, vol. 13, p. 33, 2010.
“Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.”, AIDS Res Hum Retroviruses, vol. 26, no. 10, pp. 1047-9, 2010.
“Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.”, AIDS, vol. 23, no. 3, pp. 369-75, 2009.
“HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects.”, AIDS Res Hum Retroviruses, vol. 24, no. 9, pp. 1203-8, 2008.
“Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption ”, AIDS, vol. 22, no. 10, pp. 1153-61, 2008.
“Baseline viral load and immune activation determine the extent of reconstitution of innate immune effectors in HIV-1-infected subjects undergoing antiretroviral treatment.”, J Immunol, vol. 179, no. 4, pp. 2642-50, 2007.
“Early and delayed benefits of HIV-1 suppression: timeline of recovery of innate immunity effector cells.”, AIDS, vol. 21, no. 3, pp. 293-305, 2007.
“Enhancement of the host immune responses in cutaneous T-cell lymphoma by CpG oligodeoxynucleotides and IL-15.”, Blood, vol. 104, no. 13, pp. 4142-9, 2004.
“Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.”, PLoS Med, vol. 1, no. 3, p. e64, 2004.
“HIV-1 transmission and cytokine-induced expression of DC-SIGN in human monocyte-derived macrophages.”, J Leukoc Biol, vol. 74, no. 5, pp. 757-63, 2003.
“Lessons learned from HIV treatment interruption: safety, correlates of immune control, and drug sparing.”, Curr HIV Res, vol. 1, no. 3, pp. 329-42, 2003.
“Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals.”, J Immunol, vol. 168, no. 9, pp. 4796-801, 2002.
“Sustained impairment of IFN-gamma secretion in suppressed HIV-infected patients despite mature NK cell recovery: evidence for a defective reconstitution of innate immunity.”, J Immunol, vol. 168, no. 11, pp. 5764-70, 2002.